Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on Supercritical Fluids

EDMONTON, ALBERTA--(Marketwired - May 9, 2016) -Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European Meeting on Supercritical Fluids being held in Essen, Germany.

The oral presentation entitled, "PGX Technology: An Enabling Technology for Generating Biopolymer Fibrils, Particles Aerogels and Nano-Composites," was presented by Bernhard Seifried, Ph.D., Senior Research Scientist at Ceapro and co-inventor of the PGX Technology, during the session: Materials - Organic materials, polymers and composites, chaired by Irina Smirnova.

Published: 09 May 2016
Written by Editor
Up on News   TSXV  
Read more: Ceapro Inc ( CZO )

SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction

SciVac Therapeutics changes its name to VBI Vaccines
Combined company to begin trading on The NASDAQ Capital Market under the symbol “VBIV”
Combined company is a biotechnology company with a licensed hepatitis B vaccine and a pipeline of novel technologies that seek to expand vaccine protection in large underserved markets
 
CAMBRIDGE, Mass., May 09, 2016 -- VBI Vaccines Inc., a Delaware corporation (“VBI”), and SciVac Therapeutics Inc., a British Columbia corporation (“SciVac”), are pleased to announce the completion of their previously announced merger transaction, whereby SciVac acquired VBI.  VBI survives the merger as a wholly owned subsidiary of SciVac. 
 
Upon completion of the merger, SciVac changed its name to VBI Vaccines Inc. and will commence trading on The NASDAQ Capital Market under the symbol “VBIV” at market open on March 9, 2016.
Published: 09 May 2016
Written by Editor
M & A   Up on News  
Read more: VBI Vaccines Inc ( VBIV )

Synthetic Biologics Reports First Quarter 2016 Operational Highlights and Financial Results

-- Positioned to Initiate Phase 3 Clinical Trial for SYN-010 for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in 2H 2016 --
-- Two SYN-010 Posters Scheduled for Presentation at Digestive Disease Week (DDW 2016), Including Additional Positive Results from Two Phase 2 Clinical Trials --
 
ROCKVILLE, Md., May 5, 2016 -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, today provided an operational update and reported financial results for the three months ended March 31, 2016.
 
"Our momentum from 2015 carried into the first quarter of 2016, as we continued to make important clinical progress in our microbiome-focused programs. During the quarter, we announced positive topline results from the second Phase 2 clinical trial of SYN-010 in patients with IBS-C. 
Published: 06 May 2016
Written by Editor
AMEX   Financial Results   Up on News  
Read more: Synthetic Biologics Inc ( SYN )

Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases

Interleukin Genetics Utilizes Genetic Patterns in Investigational Drug Response Evaluation
 
WALTHAM, Mass., May 04, 2016 -- Interleukin Genetics, Inc. (ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin’s IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
Published: 04 May 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Eleven Biotherapeutics Inc ( EBIO )

InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold ™ in the INSPIRE Study

2016-04-26 08:00 ET - News Release

- Four Out of First Six Patients Have Converted from Complete to Incomplete Spinal Cord Injury –

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.

The Objective Performance Criterion (OPC), a measure of study success for the INSPIRE study, is defined as 25% or more of the patients having improved by at least one AIS grade by six months post-implantation. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries have an AIS grade improvement by six months post-injury. *

Published: 26 April 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: InVivo Therapeutics ( NVIV )
  1. Summit Therapeutics plc ( SMMT )
  2. Aralez Pharmaceuticals ( ARZ / ARLZ )
  3. Pacific Biosciences of California Inc ( PACB )
  4. Parnell Pharmaceuticals Holdings Ltd ( PARN )
  5. VolitionRx Limited ( VNRX )